This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Gleaming the Cubist

Next up, an email from Fareed H., who writes, "We know you don't like Cell Therapeutics, but the company has to be worth something. What's your price target on the stock?"

I did some quick calculations and came up with a fair value for Cell Therapeutics in the range of 20 cents to 30 cents a share.

This valuation takes into account the lowered debt level and assumes the cancer drug pixantrone is approved (risk adjusted to 85%) and does $100 million in peak sales. I give no value to Opaxio because I don't believe that drug is approvable ever, nor did I give the company any credit for whatever else sits in the pipeline.

Obviously, the value of Cell Therapeutics rises if pixantrone does better or if something else from the company's pipeline is a success. At this point, I believe assuming $100 million in pixantrone sales is a generous forecast.

Jonathan L. isn't impressed with my biotech stocks picks from last week or the performance of my model portfolio.

"Your portfolio was up only 21%, what a joke. I can close my eyes throw a dart and beat 21%, and you're the one with a platform to give stock advice. What a joke. The only thing you're good at is destroying the wealth of everyday Americans after the worst economic disaster since the Depression. What you do is no less than stealing food off the tables of hard working [sic] American investors. What a joke. Let me guess next time Cell Therapeutics or Hemispherx Biopharma (HEB - Get Report) come out with good news you're going to bash them to get the stock price down, so you're [sic] hedge buddies can pick up cheap shares by costing real Americans thousands if not millions. I bet you've never worked a day in your life. You look like a [bleeping] worm. I just had to throw in that last comment. Have a nice day."
4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $0.45 1.40%
ARNA $1.58 -0.32%
CBST $101.94 0.14%
HEB $0.12 -6.20%
TEVA $53.86 0.06%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,048.02 -3.10 -0.15%
NASDAQ 4,712.6790 -12.96 -0.27%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs